ALVO Earnings Date: Nov 11, 2026 (Estimated) — Alvotech
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is ALVO's next earnings date?
Alvotech (ALVO) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.02 on revenue of $134.2M.
How did ALVO do in its last earnings report?
In its most recent report on Aug 19, 2026 (Q2 2026), Alvotech posted EPS of -$0.17 versus the -$0.05 estimate, a miss of 112.5%. Revenue was $106.0M against a $103.0M estimate. The stock's 1-day post-earnings move was +7.0%.
How much does ALVO stock move after earnings?
ALVO beat EPS estimates in 3 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 5.7% (up or down) in the day after earnings.
About Alvotech
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-19 | Q2 2026 | -0.05 | -0.17 | -112.50% | $106.0M | ❌ Miss | +7.02% | +23.06% | +47.12% |
| 2026-05-06 | Q1 2026 | 0.03 | 0.00 | -100.00% | $105.9M | ❌ Miss | -10.36% | +2.80% | -0.84% |
| 2026-03-18 | Q4 2025 | 0.05 | -0.37 | -840.00% | $168.9M | ❌ Miss | -5.79% | -17.37% | -5.00% |
| 2025-11-12 | Q3 2025 | 0.02 | -0.02 | -200.00% | $113.7M | ❌ Miss | -1.43% | -6.61% | -0.54% |
| 2025-08-13 | Q2 2025 | -0.11 | 0.14 | +227.27% | $173.2M | ✅ Beat | -5.41% | -8.26% | -10.38% |
| 2024-11-13 | Q3 2024 | -0.06 | -0.02 | +66.67% | $102.9M | ✅ Beat | +1.17% | +4.11% | -1.09% |
| 2024-08-15 | Q2 2024 | 0.00 | 0.28 | +100.00% | $198.7M | ✅ Beat | +8.72% | +0.34% | -8.80% |
| 2024-05-21 | Q1 2024 | -0.08 | -0.89 | -1012.50% | $36.9M | ❌ Miss | — | — | — |
Showing last 8 quarters.
Revenue by segment & region
By region
FY2025 · $586.3M total · annual
| Segment | Share | Revenue | YoY | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Europe | 52.4% | $307.2M | +95.0% | $63.5M | $157.6M | $307.2M |
| UNITED STATES | 41.2% | $241.4M | -11.6% | — | $273.0M | $241.4M |
| Rest Of The World | 6.4% | $37.7M | -36.1% | — | $59.1M | $37.7M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.